Lipid-based ophthalmic emulsion

US10925892B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10925892-B2
Application numberUS-201916281316-A
CountryUS
Kind codeB2
Filing dateFeb 21, 2019
Priority dateFeb 21, 2018
Publication dateFeb 23, 2021
Grant dateFeb 23, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is directed to a lipid-based ophthalmic emulsion. The emulsion has an increased amount of a mucoadhesive galactomannan polymer that promotes a long-lasting protection against desiccation and moisture retention.

First claim

Opening claim text (preview).

We claim: 1. An ophthalmic emulsion, the emulsion comprising: water forming an aqueous phase; oil forming an oil phase; a hydrophilic surfactant having an HLB value from 10 to 18; a hydrophobic surfactant having an HLB value from 1 to 6; a charged phospholipid; borate; a mucoadhesive galactomannan polymer; and a preservative; wherein the mucoadhesive galactomannan polymer is present in the emulsion at a concentration of at least about 0.13 w/v % but no greater than 0.3 w/v %; wherein the preservative is free of a benzalkonium chloride; and wherein the ophthalmic emulsion has a hydration protection against desiccation of at least 10% higher than a control emulsion, wherein the control emulsion has the same composition of the ophthalmic emulsion except of containing 0.05 w/v % of the same galactomannan polymer used in the ophthalmic emulsion. 2. The emulsion as in claim 1 wherein the oil is a hydrocarbon selected from mineral oil, paraffin oil and petrolatum. 3. The emulsion as in claim 1 wherein the oil is at least 0.1 w/v % and no greater than 3 w/v % of the emulsion. 4. The emulsion as in claim 3 wherein the hydrophilic surfactant is present in the emulsion in an amount that is at least 0.08 w/v % and is no greater than about 0.8 w/v %. 5. The emulsion as in claim 4 wherein the hydrophilic surfactant is polyoxyethylene-40-stearate. 6. The emulsion as in claim 4 wherein the hydrophobic surfactant is at least about 0.01 w/v % and is no greater than 2.0 w/v %. 7. The emulsion as in claim 6 wherein the hydrophobic surfactant is a sorbitan tristearate. 8. The emulsion as in claim 1 wherein the mucoadhesive galactomannan polymer is selected from the group consisting of guar and hydroxypropyl guar. 9. The emulsion as in claim 8 wherein the charged phospholipid is an anionic phospholipid named dimyristoyl phosphatidylglycerol. 10. The emulsion as in claim 1 further comprising a borate/polyol buffer system. 11. The emulsion as in claim 10 wherein the preservative is a polymeric quaternary ammonium compound. 12. The emulsion as in claim 1 , wherein: i. the oil phase is in droplets within the aqueous phase and the droplets have a D 90 diameter that is no greater than about 700 nm but is at least 10 nm; and ii. the borate and galactomannan polymer cooperatively act to form a gel upon instillation of the emulsion in an eye of an individual. 13. The emulsion as in claim 12 , wherein the oil phase is in droplets within the aqueous phase and the droplets have a D 90 diameter that is no greater than about 500 nm but is at least 30 nm. 14. The emulsion as in claim 13 , wherein the oil phase is in droplets within the aqueous phase and the droplets have a D 90 diameter that is no greater than about 300 nm but is at least 50 nm.

Assignees

Inventors

Classifications

  • containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids · CPC title

  • Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title

  • Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title

  • Mixtures of compounds · CPC title

  • Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10925892B2 cover?
The present invention is directed to a lipid-based ophthalmic emulsion. The emulsion has an increased amount of a mucoadhesive galactomannan polymer that promotes a long-lasting protection against desiccation and moisture retention.
Who is the assignee on this patent?
Novartis Ag, Alcon Inc
What technology area does this patent fall under?
Primary CPC classification A61K9/0048. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).